文献速递胸部肿瘤放疗放疗物理与技术

LUSTRE试验:立体定向与常规大分割放疗治疗不可手术I期非小细胞肺癌的生活质量比较

Quality of Life of Stereotactic Versus Hypofractionated Radiation Therapy for Inoperable Stage I Non-Small Cell Lung Cancer: Results From the LUSTRE Trial.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2025-11-21

LUSTRE是一项在16个加拿大中心开展的3期随机试验,纳入233例医学上不可手术的I期(≤5 cm)非小细胞肺癌患者,按2:1随机接受SBRT或CHRT。结果显示SBRT在2周时总体健康评分略优,但24个月时略低于CHRT,LC-13症状评分在2周时SBRT略优,24个月时两组无差异。

要点

  • SBRT组2周总体健康评分68.93,CHRT组64.93,差异4.00。
  • 24个月总体健康评分SBRT组59.96,CHRT组62.88,差异-2.92。

核心结论

  • 与CHRT相比,SBRT在不可手术I期NSCLC患者中提供适度的急性期生活质量获益,长期生活质量获益相似。

研究设计与样本

  • 3期随机试验,在16个加拿大中心开展,纳入233例医学上不可手术的I期(≤5 cm)NSCLC患者,按2:1随机接受SBRT或CHRT。

主要发现

  • 2周时模型估计总体健康评分SBRT组68.93,CHRT组64.93,估计平均差异4.00(95% CI 3.12, 4.89,P < .01)。
  • 24个月时总体健康评分SBRT组59.96,CHRT组62.88,差异-2.92(95% CI -3.73, -2.11,P < .01)。
  • 2周时LC-13症状评分SBRT组15.70,CHRT组17.11,差异-1.41(95% CI -1.87, -0.95,P < .01)。
  • 24个月时LC-13评分平均差异0.14(95% CI -0.29, 0.57,P = .69)。

临床怎么用

  • 对于医学上不可手术的I期NSCLC患者,SBRT可作为兼顾急性期生活质量和长期生活质量的选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: There is limited evidence on quality-of-life (QoL) outcomes of stereotactic body radiation therapy (SBRT) compared with conventionally hypofractionated radiation therapy (CHRT) in patients with medically inoperable stage I (≤5 cm) non-small cell lung cancer (NSCLC). METHODS AND MATERIALS: This phase 3 randomized trial was conducted across 16 Canadian centers, enrolling patients with medically inoperable stage I (≤5 cm) NSCLC. Participants were randomized in a 2:1 ratio to receive SBRT or CHRT. QoL was assessed over 2 years postrandomization using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 and the lung cancer-specific module 13 (LC-13), evaluating physical, symptom, functional, and social well-being. Differences in QoL between treatment groups at 2 weeks and 2 years were analyzed using linear mixed models, adjusting for baseline scores and stratification variables. RESULTS: Of the 233 patients, 154 received SBRT and 79 received CHRT. At 2 weeks, model estimated mean global health scores were higher in the SBRT group (68.93 vs 64.93), with an estimated mean difference of 4.00 (95% CI 3.12, 4.89, P < .01). At 24 months, global health scores were 59.96 for SBRT and 62.88 for CHRT, with a difference of -2.92, 95% CI: -3.73, -2.11, P < .01). Mean LC-13 symptom scores at 2 weeks were 15.70 for SBRT and 17.11 for CHRT, with a difference of -1.41 (95% CI: -1.87, -0.95, P < .01). Mean difference in LC-13 at 24 months was 0.14 (95% CI: -0.29, 0.57, P = .69). CONCLUSIONS: SBRT offers modest benefit in acute QoL and similar benefit in long-term QoL compared with CHRT in patients with inoperable stage I NSCLC.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Hou Q, Parpia S, Wierzbicki M, et al. Quality of Life of Stereotactic Versus Hypofractionated Radiation Therapy for Inoperable Stage I Non-Small Cell Lung Cancer: Results From the LUSTRE Trial. Int J Radiat Oncol Biol Phys. 2025. PMID: 41275977. doi:10.1016/j.ijrobp.2025.11.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。